Perturbation with Intrabodies Reveals That Calpain Cleavage Is Required for Degradation of Huntingtin Exon 1

• Amber L. Southwell,

  Current address: Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada

  Affiliation Division of Biology, California Institute of Technology, Pasadena, California, United States of America

  ⨯
• Charles W. Bugg,

  Affiliation Division of Biology, California Institute of Technology, Pasadena, California, United States of America

  ⨯
• Linda S. Kaltenbach,

  Affiliation Center for Drug Discovery, Department of Neurobiology, Duke University Medical Center, Durham, North Carolina, United States of America

  ⨯
• Denise Dunn,

  Affiliation Center for Drug Discovery, Department of Neurobiology, Duke University Medical Center, Durham, North Carolina, United States of America

  ⨯
• Stefanie Butland,

  Affiliation Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada

  ⨯
• Andreas Weiss,

  Affiliation Neuroscience Discovery, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland

  ⨯
• Paolo Paganetti,

  Current address: AC Immune SA, Lausanne, Switzerland

  Affiliation Neuroscience Discovery, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland

  ⨯
• Donald C. Lo,

  Affiliation Center for Drug Discovery, Department of Neurobiology, Duke University Medical Center, Durham, North Carolina, United States of America

  ⨯
• Paul H. Patterson

  * E-mail: php@caltech.edu

  Affiliation Division of Biology, California Institute of Technology, Pasadena, California, United States of America

  ⨯